Elanco Animal Health Incorporated ELAN
22.31
(0.04)
(0.18%)
as of 25 Sep
- Market cap
- $11.2B
- P/E
- 0.0×
Follow ELAN
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 287.71 |
+8 more quarters Free account |
P/S ratio |
2.45 | 2.43 | 2.38 | 2.18 | |
P/FCF ratio |
34.43 | 40.65 | 42.88 | 28.92 | |
P/Operating CF |
44.38 | 916.15 | 104.01 | 45.69 | |
P/B ratio |
1.87 | 1.83 | 1.72 | 1.48 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.12 | 3.16 | 3.12 | 2.95 | |
EV/EBITDA |
20.26 | 20.71 | 21.16 | 15.56 | |
EV/Operating CF |
25.41 | 26.82 | 26.26 | 21.50 | |
EV/FCF |
43.92 | 52.81 | 56.13 | 39.09 | |
Quick Ratio |
0.91 | 0.95 | 0.93 | 1.02 | |
Current Ratio |
2.05 | 2.16 | 2.17 | 2.40 | |
Net Debt/EBITDA |
12.10 | 10.96 | (385.78) | 19.77 | |
Debt/Assets |
28.89% | 30.18% | 30.07% | 29.70% | |
Debt/Equity |
0.59 | 0.61 | 0.61 | 0.60 | |
Asset Turnover |
0.37 | 0.37 | 0.36 | 0.34 | |
Operating CF/Net income |
5.13 | 0.23 | (0.39) | (6.44) | |
Capex/Depreciation |
(0.19) | (0.30) | (0.36) | (0.52) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6.73% | 7.08% | 8.13% | 7.83% | |
Selling, General and Administrative Expense of Revenue |
32.82% | 27.79% | 29.55% | 30.87% | |
Intangible Assets out of Total Assets |
0.59 | 0.60 | 0.61 | 0.62 | |
Share Based Compensation of Revenue |
1.46% | 1.53% | 1.40% | 1.50% | |
Graham Net Nets |
(0.26) | (0.26) | (0.30) | (0.33) | |
Graham Number |
0.00 | 0.00 | 0.00 | 4.63 | |
Earnings Yield |
(1.67%) | (2.09%) | (2.08%) | 0.35% | |
Free Cash Flow Yield |
2.90% | 2.46% | 2.33% | 3.46% | |
Revenue per Share |
2.74 | 2.75 | 2.30 | 2.29 | |
Operating CF per Share |
0.55 | 0.03 | 0.22 | 0.44 | |
Capex per Share |
(0.07) | (0.10) | (0.12) | (0.19) | |
Free Cash Flow per Share |
0.49 | (0.08) | 0.09 | 0.26 | |
Cash per Share |
1.06 | 0.86 | 1.10 | 1.02 | |
Shareholders Equity per Share |
13.19 | 13.06 | 13.19 | 13.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.19 | 13.06 | 13.19 | 13.58 | |
Free Cash Flow |
244.00 | (38.00) | 46.00 | 127.00 | |
Working Capital |
1,945.00 | 1,922.00 | 1,861.00 | 2,038.00 | |
Capital Expenditures |
(33.00) | (51.00) | (62.00) | (92.00) | |
Net Current Asset Value |
(3,176.00) | (3,138.00) | (3,353.00) | (3,309.00) | |
EV/EBIT |
193.59 | 276.30 | 980.37 | 67.96 | |
Capex to Sales |
0.02 | 0.04 | 0.05 | 0.08 | |
Net Profit Margin |
3.95% | 4.16% | (24.13%) | (2.99%) | |
Price to Operating Income |
151.76 | 212.68 | 748.90 | 50.28 | |
| Other line items | |||||
Average Receivables |
1,127.50 | 1,107.00 | 913.00 | 939.50 | |
Average Payables |
397.50 | 351.00 | 332.00 | 305.50 | |
Average Inventory |
1,719.50 | 1,654.50 | 1,655.50 | 1,670.00 | |
Average Assets |
13,651.50 | 13,081.50 | 12,986.00 | 13,417.00 | |
Average Common Equity |
6,681.50 | 6,426.50 | 6,321.50 | 6,636.00 |
Columns are period end dates